J&J Unit Veridex Licenses OncoMethylome's Prostate Cancer Dx | GenomeWeb
NEW YORK (GenomeWeb News) — OncoMethylome Sciences today said it has licensed a prostate cancer test it is developing to Johnson & Johnson subsidiary Veridex.
 
OncoMethylome said it has completed the initial research phase of the urine-based test, and said Veridex will finish developing it and will have the rights to market the resulting product worldwide.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.